DENTSPLY SIRONA (NASDAQ:XRAY) Director Brian Gladden Buys 9,985 Shares of Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Gladden bought 9,985 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was purchased at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

DENTSPLY SIRONA Trading Up 0.5%

Shares of NASDAQ XRAY opened at $10.14 on Tuesday. The firm’s 50 day moving average price is $10.95 and its 200-day moving average price is $11.71. The company has a market cap of $2.03 billion, a PE ratio of -3.22, a P/E/G ratio of 1.20 and a beta of 0.89. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $17.09. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. During the same period last year, the business earned $0.43 EPS. DENTSPLY SIRONA’s revenue was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

Analyst Ratings Changes

XRAY has been the subject of several recent analyst reports. Barrington Research boosted their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Robert W. Baird increased their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Wells Fargo & Company boosted their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Weiss Ratings cut shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Finally, UBS Group dropped their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $13.55.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently modified their holdings of XRAY. First Eagle Investment Management LLC raised its stake in DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after acquiring an additional 458,744 shares during the period. Sound Income Strategies LLC boosted its position in shares of DENTSPLY SIRONA by 32.3% in the fourth quarter. Sound Income Strategies LLC now owns 611,308 shares of the medical instruments supplier’s stock worth $7,464,000 after purchasing an additional 149,384 shares during the period. Skba Capital Management LLC increased its stake in shares of DENTSPLY SIRONA by 14.3% in the third quarter. Skba Capital Management LLC now owns 1,140,430 shares of the medical instruments supplier’s stock worth $14,472,000 after purchasing an additional 142,900 shares in the last quarter. Invenomic Capital Management LP increased its stake in shares of DENTSPLY SIRONA by 48.7% in the third quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock worth $55,217,000 after purchasing an additional 1,425,637 shares in the last quarter. Finally, Crawford Investment Counsel Inc. bought a new stake in shares of DENTSPLY SIRONA during the 3rd quarter valued at $1,104,000. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.